Search

Displaying results 631 - 640 of 10000 in total
  1. Drug

    Evolocumab

    go.drugbank.com/drugs/DB09303
    ApprovedInvestigational

    Evolocumab is designed to bind to PCSK9 and inhibit PCSK9 from binding to LDL receptors on the liver surface, resulting in more LDL receptors on the surface of the liver to remove LDL-C from the blood. … Evolocumab is a monoclonal antibody designed for the treatment of hyperlipidemia by Amgen.

    Products: REPATHA® 140 MG/ML, REPATHA 140 MG/ML SC ENJEKSIYONLUK COZELTI ICEREN KULLANIMA HAZIR ENJEKTOR, 1 ADET
  2. Drug

    Meloxicam

    go.drugbank.com/drugs/DB00814
    ApprovedInvestigationalVet approved

    Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis.

    Mixtures: MELOCAM DUO 7.5/20 MG TABLETAS RECUBIERTAS, OCAM PROTECT 15 MGCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  3. Drug

    Famotidine

    go.drugbank.com/drugs/DB00927
    ApprovedInvestigational

    disease, famotidine was about 20 to 50 times more potent at inhibiting gastric acid secretion than [cimetidine] and eight times more potent than [ranitidine] on a weight basis. … Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion.

    Mixtures: TRIGAST 10 MG/800 MG/165 MG ÇİĞNEME TABLETİ, 6 ADET, ACİDPASS 10 MG/800 MG/165 MG ÇİĞNEME TABLETİ, 2 ADETCategories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  4. Drug

    Triethylenetetramine

    go.drugbank.com/drugs/DB06824
    ApprovedInvestigational

    tolerant to [penicillamine]. … [A19333] Initially approved by the FDA in 1985 as a second-line treatment for Wilson's disease,[A19334] TETA is currently indicated to treat adults with stable Wilson’s disease who are de-coppered and

    Products: NOVİLS 250 MG SERT KAPSÜL, 100 ADET, WİLENTİN 250 MG SERT KAPSÜL, 100 ADET
  5. Drug

    Methenamine

    go.drugbank.com/drugs/DB06799
    ApprovedInvestigationalVet approved

    Methenamine is a heterocyclic organic compound with a cage-like structure similar to adamantane.

    Mixtures: PURINOL 250 mg+615 mg/5 g EFERVESAN 140 GR, PURINOL 250 mg+615 mg/5 g EFERVESAN 140 GRProducts: URON 500 MG TABLET, 1000 ADET, URON 500 MG TABLET, 500 ADET
  6. Drug

    Propylthiouracil

    go.drugbank.com/drugs/DB00550
    Approved

    Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism.

    Products: TIROSTAT 100, PROPYL TABLET 50 mg
  7. Drug

    Armodafinil

    go.drugbank.com/drugs/DB06413
    ApprovedInvestigational

    Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep … Armodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S.

    Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP2B6 InducersProducts: นูวิจิล (150 MG), NUVIGIL ®150 MG
  8. Drug

    Sevelamer

    go.drugbank.com/drugs/DB00658
    ApprovedInvestigational

    Sevelamer is a phosphate binding drug used to prevent hyperphosphataemia in patients with chronic renal failure. It is marketed by Genzyme under the trade name Renagel.

    Products: VELARIX 800 MG FILM KAPLI TABLET ,180 TB, RENVELA 2,4 G ORAL SÜSPANSIYON IÇIN TOZ, 60 SAŞE
  9. Drug

    Bosutinib

    go.drugbank.com/drugs/DB06616
    ApprovedInvestigational

    [L48436] On September 26, 2023, bosutinib was also approved by the FDA for the treatment of pediatric CML that is newly diagnosed or resistant/intolerant to prior therapy. … [A6901,A17961] Bosutinib was first approved by the FDA in 2012 for the treatment of adult chronic, accelerated, or blast-phase Ph+ CML with resistance or intolerance to prior therapy.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 InhibitorsSynonyms: 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrile
  10. Drug

    Sotalol

    go.drugbank.com/drugs/DB00489
    ApprovedInvestigational

    Sotalol is a methanesulfonanilide developed in 1960.[A178579] It was the first of the class III anti arrhythmic drugs.[A178579] Sotalol was first approved as an oral tablet on 30 October 1992.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesProducts: SOTALEX 160 MG, PMS-sotalol - 160 mg